Cipher Pharmaceuticals Proposes Adding Dr. Laurence Terrisse-Rulleau To Board of Directors

Thursday, April 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MISSISSAUGA, ON, April 26, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced

that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 19, 2018.

Dr. Rulleau is currently

a partner at CTI Life Sciences, a biotech venture capital firm that makes investments in high quality emerging life sciences companies at the pre-clinical, clinical and revenues stage in Canada and the U.S.  In her capacity as a partner, she is serving on Boards of Directors of both private and public companies in North America. Prior to this role, Dr. Rulleau served as Vice-President Business Development of Univalor, the technology transfer office of the Université de Montréal, from November 2011 to November 2014. Under her leadership at Univalor, more than 40 licenses with industry partners were signed and eight companies were formed. Prior to joining Univalor, Dr. Rulleau served as Chief Executive Officer of HLA-G Technologies, a biotechnology start-up based in France. Dr. Rulleau also has over 10 years of experience as a health sciences analyst at a several Canadian investment banks where she was involved in numerous transactions such as mergers and acquisitions, IPOs and financings. Dr. Rulleau has a Masters in Biology from The Universite du Quebec and a Ph.D. from Montreal University executed at the Montreal Clinical Research Institute

"We're pleased to attract such a highly accomplished and recognized healthcare executive to the Cipher Board," said Mark Beaudet, Chair of Cipher's Board of Directors. "Laurence brings extensive transaction and industry experience that complements and strengthens Cipher's Board of Directors."

Dr. Rulleau commented: "I have known Cipher since its initial public listing, and I'm excited to join the Board at this important stage in the Company's evolution.  Leveraging my background and relationships, I look forward to assisting the team as it continues to execute on the strategy to build a diversified portfolio of products across multiple therapeutic categories." 

About Cipher Pharmaceuticals Inc.Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store